356 related articles for article (PubMed ID: 27930388)
1. Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?
Buccisano F; Walter RB
Curr Opin Hematol; 2017 Mar; 24(2):132-138. PubMed ID: 27930388
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
3. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
4. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
5. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
[TBL] [Abstract][Full Text] [Related]
6. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
Araki D; Wood BL; Othus M; Radich JP; Halpern AB; Zhou Y; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
J Clin Oncol; 2016 Feb; 34(4):329-36. PubMed ID: 26668349
[TBL] [Abstract][Full Text] [Related]
9. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease.
Appelbaum FR
Best Pract Res Clin Haematol; 2015; 28(2-3):133-40. PubMed ID: 26590770
[TBL] [Abstract][Full Text] [Related]
11. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; Estey EH; Appelbaum FR
Blood; 2013 Sep; 122(10):1813-21. PubMed ID: 23847197
[TBL] [Abstract][Full Text] [Related]
12. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
13. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?
Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Biol Blood Marrow Transplant; 2017 Apr; 23(4):588-597. PubMed ID: 28089879
[TBL] [Abstract][Full Text] [Related]
15. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.
Fasan O
Curr Opin Hematol; 2019 Nov; 26(6):413-420. PubMed ID: 31503019
[TBL] [Abstract][Full Text] [Related]
16. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
[TBL] [Abstract][Full Text] [Related]
17. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
19. Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?
Venditti A; Gale RP; Buccisano F; Ossenkoppele G
Leukemia; 2020 Apr; 34(4):963-965. PubMed ID: 32132654
[No Abstract] [Full Text] [Related]
20. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
Cassaday RD; Alan Potts D; Stevenson PA; Bar M; Georges GE; Shustov AR; Sorror ML; Wood BL; Delaney C; Doney KC; Storb RF; Sandmaier BM
Leuk Lymphoma; 2016 Sep; 57(9):2109-18. PubMed ID: 27002921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
